Sales are negligible relative to market cap and follow option exercises, consistent with routine liquidity/vesting activity. No bearish read-through. Monitor next earnings for fundamental signals.
CORT drugs
CORT drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 7 $110.77entry
- T+1 · 3mo ago +3.12%α +3.15% · $114.23
- T+5 · 3mo ago +3.34%α +2.94% · $114.47
- T+20 · 2mo ago +0.77%α +1.16% · $111.62
- T+60 · 15d ago −27.08%α −24.95% · $80.77
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three executives at Corcept Therapeutics sold a combined $3.88M in open-market stock over a 7-day window, including the CFO and Chief Development Officer. At a $12B market cap, this represents ~0.03%, a trivial proportion, making it routine portfolio diversification rather than a bearish signal. The sales follow recent option exercises and align with typical vesting-related liquidity patterns.
Key Financial Metrics
Key Facts
- Three insiders sold $3.88M total in open-market sales over 7 days.
- Total sales represent ~0.03% of the $12.0B market cap.
- CFO Atabak Mokari sold 9,000 shares ($958K) at $106.96.
- Sean Maduck sold 20,305 shares ($2.33M) at $114.70 after exercising options.
- William Guyer sold 3,700 shares ($419K) at $113.12 after exercising options.
- Joseph Lyon sold 1,540 shares ($176K) at $114.16.
- No open-market purchases were recorded in the cluster.
Financial Impact
0.03% of market cap sold, trivial
Risk Factors
- Insider selling may intensify ahead of a catalyst (upcoming earnings or trial data).
- Option exercises could precede further open-market sales from other executives.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-CORT-1786057272652 |
Track record
36 reports on CORT
8 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +63.06% at T+60 after the Feb 24, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $73.87 Now $72.94 −1.26% settles Dec 15
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $74.53 Now $72.94 −2.13% settles Dec 10
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $71.63 Now $72.94 +1.83% settles Dec 4
- Nov 3, 202613d ago 8-K Bullish 6/10 Entry $79.22 Now $72.94 −7.93% settles Dec 3
- Nov 2, 202614d ago Institutional Cluster Bearish 4/10 Entry $81.93 Now $72.94 +10.97% settles Dec 2
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $86.28 Now $72.94 −15.46% settles Nov 25
- Oct 5, 20266w ago Insider Cluster Neutral 3/10 Entry $119.57 to $81.93 Now $72.94 −39.00% ▼ −31.48% −28.30% vs SPY
- Sep 23, 20267w ago 8-K Neutral 3/10 Entry $112.94 to $116.28 Now $72.94 −35.42% ▲ +2.96% +2.27% vs SPY
- Sep 16, 20268w ago Insider Cluster Bearish 4/10 Entry $114.86 to $113.37 Now $72.94 +36.50% ▲ +1.30% +2.50% vs SPY
- Sep 16, 20268w ago Insider Cluster Bearish 4/10 Entry $114.86 to $113.37 Now $72.94 +36.50% ▲ +1.30% +2.75% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers